nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Mitomycin—urinary bladder cancer	0.316	0.506	CbGbCtD
Nadolol—ABCB1—Gemcitabine—urinary bladder cancer	0.091	0.146	CbGbCtD
Nadolol—ABCB1—Cisplatin—urinary bladder cancer	0.0661	0.106	CbGbCtD
Nadolol—ABCB1—Etoposide—urinary bladder cancer	0.065	0.104	CbGbCtD
Nadolol—ABCB1—Doxorubicin—urinary bladder cancer	0.0443	0.0708	CbGbCtD
Nadolol—ABCB1—Methotrexate—urinary bladder cancer	0.0429	0.0686	CbGbCtD
Nadolol—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00119	0.00318	CcSEcCtD
Nadolol—Dysarthria—Epirubicin—urinary bladder cancer	0.00119	0.00318	CcSEcCtD
Nadolol—Nausea—Mitomycin—urinary bladder cancer	0.00118	0.00314	CcSEcCtD
Nadolol—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00116	0.0031	CcSEcCtD
Nadolol—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.00115	0.00308	CcSEcCtD
Nadolol—Vision blurred—Thiotepa—urinary bladder cancer	0.00115	0.00307	CcSEcCtD
Nadolol—Bradycardia—Cisplatin—urinary bladder cancer	0.00112	0.00299	CcSEcCtD
Nadolol—Dysarthria—Doxorubicin—urinary bladder cancer	0.0011	0.00294	CcSEcCtD
Nadolol—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.00107	0.00287	CcSEcCtD
Nadolol—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.00107	0.00286	CcSEcCtD
Nadolol—Fluid retention—Epirubicin—urinary bladder cancer	0.00107	0.00285	CcSEcCtD
Nadolol—Cough—Thiotepa—urinary bladder cancer	0.00107	0.00285	CcSEcCtD
Nadolol—Visual impairment—Cisplatin—urinary bladder cancer	0.00106	0.00283	CcSEcCtD
Nadolol—Hypertension—Thiotepa—urinary bladder cancer	0.00105	0.00282	CcSEcCtD
Nadolol—Agranulocytosis—Etoposide—urinary bladder cancer	0.00105	0.0028	CcSEcCtD
Nadolol—Alopecia—Gemcitabine—urinary bladder cancer	0.00104	0.00278	CcSEcCtD
Nadolol—Dry eye—Epirubicin—urinary bladder cancer	0.00104	0.00277	CcSEcCtD
Nadolol—Tinnitus—Cisplatin—urinary bladder cancer	0.00103	0.00274	CcSEcCtD
Nadolol—Alopecia—Fluorouracil—urinary bladder cancer	0.00103	0.00274	CcSEcCtD
Nadolol—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.001	0.00267	CcSEcCtD
Nadolol—Fluid retention—Doxorubicin—urinary bladder cancer	0.000988	0.00264	CcSEcCtD
Nadolol—Alopecia—Cisplatin—urinary bladder cancer	0.000972	0.0026	CcSEcCtD
Nadolol—Dry eye—Doxorubicin—urinary bladder cancer	0.000961	0.00257	CcSEcCtD
Nadolol—Vision blurred—Fluorouracil—urinary bladder cancer	0.000952	0.00254	CcSEcCtD
Nadolol—Anorexia—Thiotepa—urinary bladder cancer	0.00095	0.00254	CcSEcCtD
Nadolol—Flatulence—Cisplatin—urinary bladder cancer	0.000943	0.00252	CcSEcCtD
Nadolol—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.000926	0.00247	CcSEcCtD
Nadolol—Visual disturbance—Methotrexate—urinary bladder cancer	0.000921	0.00246	CcSEcCtD
Nadolol—Vision blurred—Cisplatin—urinary bladder cancer	0.000902	0.00241	CcSEcCtD
Nadolol—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.0009	0.0024	CcSEcCtD
Nadolol—Cough—Gemcitabine—urinary bladder cancer	0.000896	0.00239	CcSEcCtD
Nadolol—Paraesthesia—Thiotepa—urinary bladder cancer	0.000895	0.00239	CcSEcCtD
Nadolol—Alopecia—Etoposide—urinary bladder cancer	0.00089	0.00238	CcSEcCtD
Nadolol—Lethargy—Methotrexate—urinary bladder cancer	0.00089	0.00238	CcSEcCtD
Nadolol—Hypertension—Gemcitabine—urinary bladder cancer	0.000887	0.00237	CcSEcCtD
Nadolol—Dyspepsia—Thiotepa—urinary bladder cancer	0.000877	0.00234	CcSEcCtD
Nadolol—Chest pain—Gemcitabine—urinary bladder cancer	0.000874	0.00234	CcSEcCtD
Nadolol—Decreased appetite—Thiotepa—urinary bladder cancer	0.000866	0.00231	CcSEcCtD
Nadolol—Chest pain—Fluorouracil—urinary bladder cancer	0.00086	0.0023	CcSEcCtD
Nadolol—Fatigue—Thiotepa—urinary bladder cancer	0.000859	0.00229	CcSEcCtD
Nadolol—Pain—Thiotepa—urinary bladder cancer	0.000852	0.00228	CcSEcCtD
Nadolol—Constipation—Thiotepa—urinary bladder cancer	0.000852	0.00228	CcSEcCtD
Nadolol—Oedema—Gemcitabine—urinary bladder cancer	0.000838	0.00224	CcSEcCtD
Nadolol—Cardiac failure—Epirubicin—urinary bladder cancer	0.000837	0.00223	CcSEcCtD
Nadolol—Lethargy—Epirubicin—urinary bladder cancer	0.000833	0.00223	CcSEcCtD
Nadolol—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000833	0.00222	CcSEcCtD
Nadolol—Irritability—Methotrexate—urinary bladder cancer	0.000833	0.00222	CcSEcCtD
Nadolol—Mood swings—Methotrexate—urinary bladder cancer	0.000826	0.00221	CcSEcCtD
Nadolol—Oedema—Fluorouracil—urinary bladder cancer	0.000824	0.0022	CcSEcCtD
Nadolol—Diplopia—Epirubicin—urinary bladder cancer	0.000816	0.00218	CcSEcCtD
Nadolol—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00081	0.00216	CcSEcCtD
Nadolol—Affect lability—Epirubicin—urinary bladder cancer	0.000804	0.00215	CcSEcCtD
Nadolol—Anorexia—Gemcitabine—urinary bladder cancer	0.000799	0.00213	CcSEcCtD
Nadolol—Body temperature increased—Thiotepa—urinary bladder cancer	0.000788	0.0021	CcSEcCtD
Nadolol—Anorexia—Fluorouracil—urinary bladder cancer	0.000786	0.0021	CcSEcCtD
Nadolol—Hypotension—Gemcitabine—urinary bladder cancer	0.000783	0.00209	CcSEcCtD
Nadolol—Oedema—Cisplatin—urinary bladder cancer	0.000781	0.00209	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000774	0.00207	CcSEcCtD
Nadolol—Mood swings—Epirubicin—urinary bladder cancer	0.000773	0.00207	CcSEcCtD
Nadolol—Loss of consciousness—Etoposide—urinary bladder cancer	0.000771	0.00206	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—urinary bladder cancer	0.000771	0.00206	CcSEcCtD
Nadolol—Hypotension—Fluorouracil—urinary bladder cancer	0.00077	0.00206	CcSEcCtD
Nadolol—Cough—Etoposide—urinary bladder cancer	0.000765	0.00204	CcSEcCtD
Nadolol—Insomnia—Gemcitabine—urinary bladder cancer	0.000758	0.00203	CcSEcCtD
Nadolol—Hypertension—Etoposide—urinary bladder cancer	0.000757	0.00202	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—urinary bladder cancer	0.000755	0.00202	CcSEcCtD
Nadolol—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000755	0.00202	CcSEcCtD
Nadolol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000753	0.00201	CcSEcCtD
Nadolol—Dry skin—Epirubicin—urinary bladder cancer	0.000748	0.002	CcSEcCtD
Nadolol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000747	0.002	CcSEcCtD
Nadolol—Chest pain—Etoposide—urinary bladder cancer	0.000747	0.00199	CcSEcCtD
Nadolol—Insomnia—Fluorouracil—urinary bladder cancer	0.000745	0.00199	CcSEcCtD
Nadolol—Anorexia—Cisplatin—urinary bladder cancer	0.000745	0.00199	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—urinary bladder cancer	0.000744	0.00199	CcSEcCtD
Nadolol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00074	0.00198	CcSEcCtD
Nadolol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000735	0.00196	CcSEcCtD
Nadolol—Hypotension—Cisplatin—urinary bladder cancer	0.00073	0.00195	CcSEcCtD
Nadolol—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000729	0.00195	CcSEcCtD
Nadolol—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000726	0.00194	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000723	0.00193	CcSEcCtD
Nadolol—Fatigue—Gemcitabine—urinary bladder cancer	0.000723	0.00193	CcSEcCtD
Nadolol—Gastritis—Epirubicin—urinary bladder cancer	0.000723	0.00193	CcSEcCtD
Nadolol—Pain—Gemcitabine—urinary bladder cancer	0.000717	0.00191	CcSEcCtD
Nadolol—Constipation—Gemcitabine—urinary bladder cancer	0.000717	0.00191	CcSEcCtD
Nadolol—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000716	0.00191	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—urinary bladder cancer	0.000716	0.00191	CcSEcCtD
Nadolol—Asthenia—Thiotepa—urinary bladder cancer	0.000715	0.00191	CcSEcCtD
Nadolol—Abdominal distension—Epirubicin—urinary bladder cancer	0.00071	0.0019	CcSEcCtD
Nadolol—Pruritus—Thiotepa—urinary bladder cancer	0.000705	0.00188	CcSEcCtD
Nadolol—Pain—Fluorouracil—urinary bladder cancer	0.000705	0.00188	CcSEcCtD
Nadolol—Paraesthesia—Cisplatin—urinary bladder cancer	0.000702	0.00187	CcSEcCtD
Nadolol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000697	0.00186	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000694	0.00185	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—urinary bladder cancer	0.000692	0.00185	CcSEcCtD
Nadolol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000692	0.00185	CcSEcCtD
Nadolol—Anorexia—Etoposide—urinary bladder cancer	0.000682	0.00182	CcSEcCtD
Nadolol—Diarrhoea—Thiotepa—urinary bladder cancer	0.000682	0.00182	CcSEcCtD
Nadolol—Decreased appetite—Cisplatin—urinary bladder cancer	0.000679	0.00181	CcSEcCtD
Nadolol—Depression—Methotrexate—urinary bladder cancer	0.00067	0.00179	CcSEcCtD
Nadolol—Hypotension—Etoposide—urinary bladder cancer	0.000669	0.00179	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—urinary bladder cancer	0.000669	0.00179	CcSEcCtD
Nadolol—Pain—Cisplatin—urinary bladder cancer	0.000668	0.00178	CcSEcCtD
Nadolol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000663	0.00177	CcSEcCtD
Nadolol—Dizziness—Thiotepa—urinary bladder cancer	0.000659	0.00176	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000657	0.00176	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000653	0.00175	CcSEcCtD
Nadolol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000652	0.00174	CcSEcCtD
Nadolol—Sweating—Methotrexate—urinary bladder cancer	0.000644	0.00172	CcSEcCtD
Nadolol—Paraesthesia—Etoposide—urinary bladder cancer	0.000643	0.00172	CcSEcCtD
Nadolol—Weight increased—Epirubicin—urinary bladder cancer	0.000642	0.00172	CcSEcCtD
Nadolol—Dyspnoea—Etoposide—urinary bladder cancer	0.000638	0.0017	CcSEcCtD
Nadolol—Vomiting—Thiotepa—urinary bladder cancer	0.000634	0.00169	CcSEcCtD
Nadolol—Rash—Thiotepa—urinary bladder cancer	0.000628	0.00168	CcSEcCtD
Nadolol—Dermatitis—Thiotepa—urinary bladder cancer	0.000628	0.00168	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000627	0.00168	CcSEcCtD
Nadolol—Decreased appetite—Etoposide—urinary bladder cancer	0.000622	0.00166	CcSEcCtD
Nadolol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000618	0.00165	CcSEcCtD
Nadolol—Fatigue—Etoposide—urinary bladder cancer	0.000617	0.00165	CcSEcCtD
Nadolol—Pain—Etoposide—urinary bladder cancer	0.000612	0.00163	CcSEcCtD
Nadolol—Constipation—Etoposide—urinary bladder cancer	0.000612	0.00163	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000612	0.00163	CcSEcCtD
Nadolol—Sweating—Epirubicin—urinary bladder cancer	0.000603	0.00161	CcSEcCtD
Nadolol—Asthenia—Gemcitabine—urinary bladder cancer	0.000601	0.00161	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—urinary bladder cancer	0.000594	0.00159	CcSEcCtD
Nadolol—Pruritus—Gemcitabine—urinary bladder cancer	0.000593	0.00158	CcSEcCtD
Nadolol—Nausea—Thiotepa—urinary bladder cancer	0.000592	0.00158	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000587	0.00157	CcSEcCtD
Nadolol—Pruritus—Fluorouracil—urinary bladder cancer	0.000583	0.00156	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—urinary bladder cancer	0.000582	0.00155	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—urinary bladder cancer	0.000575	0.00154	CcSEcCtD
Nadolol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000574	0.00153	CcSEcCtD
Nadolol—Body temperature increased—Etoposide—urinary bladder cancer	0.000566	0.00151	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000566	0.00151	CcSEcCtD
Nadolol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000564	0.00151	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—urinary bladder cancer	0.000563	0.0015	CcSEcCtD
Nadolol—Asthenia—Cisplatin—urinary bladder cancer	0.000561	0.0015	CcSEcCtD
Nadolol—Sweating—Doxorubicin—urinary bladder cancer	0.000558	0.00149	CcSEcCtD
Nadolol—Dizziness—Fluorouracil—urinary bladder cancer	0.000545	0.00146	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—urinary bladder cancer	0.000544	0.00145	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000543	0.00145	CcSEcCtD
Nadolol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000535	0.00143	CcSEcCtD
Nadolol—Alopecia—Methotrexate—urinary bladder cancer	0.000533	0.00142	CcSEcCtD
Nadolol—Vomiting—Gemcitabine—urinary bladder cancer	0.000533	0.00142	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000532	0.00142	CcSEcCtD
Nadolol—Rash—Gemcitabine—urinary bladder cancer	0.000529	0.00141	CcSEcCtD
Nadolol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000528	0.00141	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—urinary bladder cancer	0.000527	0.00141	CcSEcCtD
Nadolol—Vomiting—Fluorouracil—urinary bladder cancer	0.000524	0.0014	CcSEcCtD
Nadolol—Rash—Fluorouracil—urinary bladder cancer	0.00052	0.00139	CcSEcCtD
Nadolol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000519	0.00139	CcSEcCtD
Nadolol—Asthenia—Etoposide—urinary bladder cancer	0.000514	0.00137	CcSEcCtD
Nadolol—Pruritus—Etoposide—urinary bladder cancer	0.000506	0.00135	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000504	0.00135	CcSEcCtD
Nadolol—Alopecia—Epirubicin—urinary bladder cancer	0.000499	0.00133	CcSEcCtD
Nadolol—Nausea—Gemcitabine—urinary bladder cancer	0.000498	0.00133	CcSEcCtD
Nadolol—Vomiting—Cisplatin—urinary bladder cancer	0.000497	0.00133	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—urinary bladder cancer	0.000495	0.00132	CcSEcCtD
Nadolol—Rash—Cisplatin—urinary bladder cancer	0.000493	0.00132	CcSEcCtD
Nadolol—Dermatitis—Cisplatin—urinary bladder cancer	0.000492	0.00131	CcSEcCtD
Nadolol—Diarrhoea—Etoposide—urinary bladder cancer	0.00049	0.00131	CcSEcCtD
Nadolol—Nausea—Fluorouracil—urinary bladder cancer	0.00049	0.00131	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—urinary bladder cancer	0.000487	0.0013	CcSEcCtD
Nadolol—Flatulence—Epirubicin—urinary bladder cancer	0.000484	0.00129	CcSEcCtD
Nadolol—Dizziness—Etoposide—urinary bladder cancer	0.000473	0.00126	CcSEcCtD
Nadolol—Nausea—Cisplatin—urinary bladder cancer	0.000464	0.00124	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—urinary bladder cancer	0.000463	0.00124	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—urinary bladder cancer	0.000462	0.00123	CcSEcCtD
Nadolol—Cough—Methotrexate—urinary bladder cancer	0.000458	0.00122	CcSEcCtD
Nadolol—Vomiting—Etoposide—urinary bladder cancer	0.000455	0.00122	CcSEcCtD
Nadolol—Rash—Etoposide—urinary bladder cancer	0.000451	0.00121	CcSEcCtD
Nadolol—Dermatitis—Etoposide—urinary bladder cancer	0.000451	0.0012	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—urinary bladder cancer	0.000448	0.0012	CcSEcCtD
Nadolol—Chest pain—Methotrexate—urinary bladder cancer	0.000447	0.00119	CcSEcCtD
Nadolol—Syncope—Epirubicin—urinary bladder cancer	0.000441	0.00118	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000432	0.00115	CcSEcCtD
Nadolol—Cough—Epirubicin—urinary bladder cancer	0.000429	0.00115	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000429	0.00115	CcSEcCtD
Nadolol—Nausea—Etoposide—urinary bladder cancer	0.000425	0.00114	CcSEcCtD
Nadolol—Hypertension—Epirubicin—urinary bladder cancer	0.000424	0.00113	CcSEcCtD
Nadolol—Chest pain—Epirubicin—urinary bladder cancer	0.000419	0.00112	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000414	0.00111	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—urinary bladder cancer	0.000409	0.00109	CcSEcCtD
Nadolol—Anorexia—Methotrexate—urinary bladder cancer	0.000409	0.00109	CcSEcCtD
Nadolol—Syncope—Doxorubicin—urinary bladder cancer	0.000408	0.00109	CcSEcCtD
Nadolol—Oedema—Epirubicin—urinary bladder cancer	0.000401	0.00107	CcSEcCtD
Nadolol—Hypotension—Methotrexate—urinary bladder cancer	0.000401	0.00107	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.0004	0.00107	CcSEcCtD
Nadolol—Cough—Doxorubicin—urinary bladder cancer	0.000397	0.00106	CcSEcCtD
Nadolol—Shock—Epirubicin—urinary bladder cancer	0.000395	0.00105	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—urinary bladder cancer	0.000393	0.00105	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000388	0.00104	CcSEcCtD
Nadolol—Insomnia—Methotrexate—urinary bladder cancer	0.000388	0.00104	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—urinary bladder cancer	0.000387	0.00103	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000385	0.00103	CcSEcCtD
Nadolol—Anorexia—Epirubicin—urinary bladder cancer	0.000382	0.00102	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000382	0.00102	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000379	0.00101	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000377	0.00101	CcSEcCtD
Nadolol—Hypotension—Epirubicin—urinary bladder cancer	0.000375	0.001	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000373	0.000995	CcSEcCtD
Nadolol—Oedema—Doxorubicin—urinary bladder cancer	0.000371	0.000992	CcSEcCtD
Nadolol—Fatigue—Methotrexate—urinary bladder cancer	0.00037	0.000987	CcSEcCtD
Nadolol—Pain—Methotrexate—urinary bladder cancer	0.000367	0.000979	CcSEcCtD
Nadolol—Shock—Doxorubicin—urinary bladder cancer	0.000365	0.000976	CcSEcCtD
Nadolol—Insomnia—Epirubicin—urinary bladder cancer	0.000363	0.000969	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—urinary bladder cancer	0.00036	0.000962	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000359	0.000959	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000358	0.000955	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—urinary bladder cancer	0.000354	0.000945	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000353	0.000943	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—urinary bladder cancer	0.000349	0.000932	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—urinary bladder cancer	0.000347	0.000927	CcSEcCtD
Nadolol—Fatigue—Epirubicin—urinary bladder cancer	0.000346	0.000924	CcSEcCtD
Nadolol—Pain—Epirubicin—urinary bladder cancer	0.000343	0.000916	CcSEcCtD
Nadolol—Constipation—Epirubicin—urinary bladder cancer	0.000343	0.000916	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000339	0.000905	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—urinary bladder cancer	0.000336	0.000897	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000333	0.00089	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000331	0.000884	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000327	0.000873	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000323	0.000862	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—urinary bladder cancer	0.00032	0.000855	CcSEcCtD
Nadolol—Pain—Doxorubicin—urinary bladder cancer	0.000317	0.000848	CcSEcCtD
Nadolol—Constipation—Doxorubicin—urinary bladder cancer	0.000317	0.000848	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000317	0.000847	CcSEcCtD
Nadolol—Asthenia—Methotrexate—urinary bladder cancer	0.000308	0.000822	CcSEcCtD
Nadolol—Pruritus—Methotrexate—urinary bladder cancer	0.000303	0.00081	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000293	0.000784	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000293	0.000784	CcSEcCtD
Nadolol—Asthenia—Epirubicin—urinary bladder cancer	0.000288	0.000769	CcSEcCtD
Nadolol—Pruritus—Epirubicin—urinary bladder cancer	0.000284	0.000758	CcSEcCtD
Nadolol—Dizziness—Methotrexate—urinary bladder cancer	0.000284	0.000757	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000275	0.000733	CcSEcCtD
Nadolol—Vomiting—Methotrexate—urinary bladder cancer	0.000273	0.000728	CcSEcCtD
Nadolol—Rash—Methotrexate—urinary bladder cancer	0.00027	0.000722	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—urinary bladder cancer	0.00027	0.000721	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—urinary bladder cancer	0.000266	0.000711	CcSEcCtD
Nadolol—Dizziness—Epirubicin—urinary bladder cancer	0.000265	0.000709	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—urinary bladder cancer	0.000263	0.000702	CcSEcCtD
Nadolol—Vomiting—Epirubicin—urinary bladder cancer	0.000255	0.000681	CcSEcCtD
Nadolol—Nausea—Methotrexate—urinary bladder cancer	0.000255	0.00068	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000254	0.000678	CcSEcCtD
Nadolol—Rash—Epirubicin—urinary bladder cancer	0.000253	0.000676	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—urinary bladder cancer	0.000253	0.000675	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—urinary bladder cancer	0.000246	0.000656	CcSEcCtD
Nadolol—Nausea—Epirubicin—urinary bladder cancer	0.000238	0.000637	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—urinary bladder cancer	0.000236	0.00063	CcSEcCtD
Nadolol—Rash—Doxorubicin—urinary bladder cancer	0.000234	0.000625	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000234	0.000625	CcSEcCtD
Nadolol—Nausea—Doxorubicin—urinary bladder cancer	0.000221	0.000589	CcSEcCtD
